Sagimet Biosciences (SGMT) grants director Kemble George 39,567 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sagimet Biosciences Inc. granted director Kemble George a stock option covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. The option expires on June 11, 2036 and represents 39,567 derivative shares held after this grant.
According to the award terms, the shares underlying this option vest in twelve equal monthly installments following June 12, 2026, conditioned on his continued service on each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kemble George
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 39,567 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 39,567 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option shares granted: 39,567 shares
Exercise price: $6.48 per share
Total derivative shares after grant: 39,567 shares
+3 more
6 metrics
Option shares granted
39,567 shares
Stock Option (Right to Buy) awarded to director Kemble George
Exercise price
$6.48 per share
Conversion or exercise price for the stock option
Total derivative shares after grant
39,567 shares
Total shares underlying options following this transaction
Expiration date
June 11, 2036
Option’s stated expiration date
Vesting schedule
12 equal monthly installments
Vesting over twelve months following June 12, 2026
Vesting start reference date
June 12, 2026
Installments vest monthly after this date, subject to continued service
Key Terms
Stock Option (Right to Buy), Series A Common Stock, exercise price, vest and become exercisable, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Series A Common Stock financial
"underlying_security_title: "Series A Common Stock""
Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.
exercise price financial
"conversion_or_exercise_price: "6.4800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments"
expiration date financial
"expiration_date: "2036-06-11T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Sagimet Biosciences director Kemble George receive in this SGMT filing?
Director Kemble George received a stock option award for 39,567 shares of Series A Common Stock at a $6.48 exercise price. This option is compensation-related and does not reflect an open-market stock purchase or sale.
What is the exercise price of Kemble George’s Sagimet Biosciences option grant?
The exercise price is $6.48 per share for the 39,567-share stock option. This means George must pay $6.48 for each share if he chooses to exercise the option once it has vested and become exercisable.
When do Kemble George’s Sagimet Biosciences options start vesting?
The shares underlying this option begin vesting after June 12, 2026. Vesting occurs in twelve equal monthly installments, and each installment requires Kemble George to remain in service through the applicable vesting date.
What is the expiration date of the Sagimet Biosciences (SGMT) option grant?
The option expires on June 11, 2036, giving up to roughly ten years from grant for potential exercise. Any shares not exercised by that date will no longer be available under this option award.